Certolizumab Pegol

證據等級: L5

預測適應症: 10 個

Using the Evidence Pack provided, I’ve synthesized a report. Note: unlike a typical single-indication candidate, this Evidence Pack (TW-DB08904-multi) contains 10 TxGNN-predicted indications for certolizumab pegol with very different evidence quality — including one (highest model score) that is actually a safety signal against use, and several that are model noise. I’ve adapted the template’s tables to reflect this honestly rather than force-fitting a single “top” prediction, per the “no guessing / explain every change” rule.

Certolizumab Pegol: From Established Anti-TNF Indications to Inflammatory Spondylopathy (Multi-Indication TxGNN Assessment)

One-Sentence Summary

Certolizumab pegol is a PEGylated anti-TNF-α biologic already established internationally for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, but it is not currently marketed in Australia (0 ARTG entries). TxGNN generated 10 candidate indications for this drug; the best-supported new-market opportunity is inflammatory spondylopathy / axial spondyloarthritis, backed by 6+ completed Phase 3 trials and multiple systematic reviews, while the model’s highest-scoring prediction (rheumatoid vasculitis) is actually contradicted by safety literature showing the drug can induce vasculitis rather than treat it. Several other candidates (e.g. congenital/structural syndromes) have no supporting evidence at all and are best treated as prediction noise.

Quick Overview

Item	Content
Original (global) indications	Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn’s disease (anti-TNF biologic; per literature evidence, e.g. PMID 27704400, 24919863)
Highest TxGNN-Scored Indication	Rheumatoid vasculitis (99.78%) — flagged Hold, safety signal contradicts efficacy hypothesis
Best-Evidenced New Indication	Inflammatory spondylopathy / axial spondyloarthritis (99.73%)
Evidence Level (best candidate)	L1
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails (inflammatory spondylopathy, vertebral disease); Research Question (polyarticular JIA, tenosynovitis); Hold (rheumatoid vasculitis and all congenital/structural predictions)

Predicted Indications — Full Ranking

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Rheumatoid vasculitis	99.78%	L4	Hold (safety contradiction)
2	Hypermobility of coccyx	99.75%	L5	Hold (no biological plausibility)
3	Inflammatory spondylopathy	99.73%	L1	Proceed with Guardrails
4	Kummell disease	99.70%	L5	Hold (no biological plausibility)
5	Polyarticular juvenile rheumatoid arthritis	99.69%	L2	Research Question
6	Vertebral disease	99.26%	L1	Proceed with Guardrails
7	Mendelian susceptibility to mycobacterial disease (IL12B deficiency)	96.85%	L5	Hold (mechanistic contraindication)
8	Brachydactyly-syndactyly syndrome	96.01%	L5	Hold (no biological plausibility)
9	Colobomatous microphthalmia-rhizomelic dysplasia syndrome	95.72%	L5	Hold (no biological plausibility)
10	Tenosynovitis	95.69%	L5	Research Question

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not returned for this drug in the Evidence Pack (data gap, DG002). Based on the literature evidence collected, certolizumab pegol is a Fc-free, PEGylated Fab’ fragment that selectively neutralises TNF-α; it lacks the antibody Fc region, so it does not fix complement or trigger antibody-dependent cytotoxicity, distinguishing it pharmacologically from other anti-TNF agents (PMID 27704400, 24919863).

For inflammatory spondylopathy / vertebral disease, this is not a novel repurposing hypothesis but a known, established anti-TNF class indication (axial spondyloarthritis and ankylosing spondylitis) that the drug simply has not yet been registered for in Australia. TNF-α is central to synovial and enthesial inflammation in spondyloarthropathies, and certolizumab pegol has multiple dedicated Phase 3 RCTs (RAPID-axSpA, C-OPTIMISE, C-axSpAnd) directly demonstrating efficacy in this population. The prediction therefore represents market expansion of a proven mechanism, not a mechanistic leap.

For polyarticular juvenile rheumatoid arthritis, the mechanistic link is a reasonable extension (shared TNF-α-driven synovitis with adult RA) and is supported by a dedicated Phase 3 PK/safety/efficacy trial (NCT01550003), but no published results were found in this pack, so evidence remains incomplete.

For rheumatoid vasculitis, the mechanistic story is inverted: the literature returned by this search consists overwhelmingly of case reports of certolizumab-induced vasculitis and related autoimmune adverse reactions (leukocytoclastic vasculitis, hypocomplementemic urticarial vasculitis, medium-vessel vasculitis, rapidly progressive glomerulonephritis), with only a single case report supporting therapeutic benefit (leg ulcers in rheumatoid vasculitis, PMID 34786446). The model’s high similarity score here appears to reflect shared disease/drug co-occurrence in the literature rather than a genuine treatment signal.

The remaining low-ranked predictions (hypermobility of coccyx, Kummell disease, brachydactyly-syndactyly syndrome, colobomatous microphthalmia-rhizomelic dysplasia syndrome) are structural, congenital, or degenerative conditions with no inflammatory/immune component and no supporting trials or literature — these are assessed as model noise. Mendelian susceptibility to mycobacterial disease due to IL12B deficiency is a distinct case: anti-TNF agents are well known to increase mycobacterial reactivation risk, so this prediction runs counter to the drug’s known risk profile and should be treated as a potential contraindication signal, not an opportunity.

Clinical Trial Evidence

(Trials shown relate primarily to the inflammatory spondylopathy / vertebral disease group, plus the dedicated polyarticular JIA trial; rows 1–7 are shared across both indications given their overlapping trial evidence.)

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01087762	Phase 3	Completed	325	Randomised, double-blind, placebo-controlled trial of two CZP dose regimens in active axial spondyloarthritis
NCT02505542	Phase 3	Completed	736	C-OPTIMISE: maintenance of remission with CZP 200mg Q2W/Q4W vs placebo in axSpA
NCT02552212	Phase 3	Completed	317	C-axSpAnd: CZP efficacy/safety in non-radiographic axSpA with objective inflammation signs
NCT01087788	Phase 3	Completed	409	CZP efficacy/safety in adult-onset active and progressive psoriatic arthritis
NCT03215277	Phase 2A	Completed	76	Head-to-head bimekizumab vs certolizumab pegol in active ankylosing spondylitis
NCT02354105	N/A (real-world)	Completed	680	Non-interventional real-world effectiveness of CZP in axSpA daily practice
NCT03020992	Phase 4	Completed	89	C-VIEW: CZP reduces anterior uveitis flares in axSpA patients with uveitis history
NCT01550003	Phase 3	Completed	193	Pharmacokinetics, safety and efficacy of CZP in children/adolescents with polyarticular JIA

No dedicated clinical trials support rheumatoid vasculitis, hypermobility of coccyx, Kummell disease, mendelian susceptibility to mycobacterial disease, brachydactyly-syndactyly syndrome, colobomatous microphthalmia-rhizomelic dysplasia syndrome, or tenosynovitis as treatment indications.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36270657	2023	Systematic Review	Ann Rheum Dis	Efficacy/safety of biological DMARDs informing 2022 ASAS-EULAR axSpA management recommendations
27366922	2016	Systematic Review	Expert Opin Biol Ther	Review of certolizumab pegol for treating axial spondyloarthritis
38503473	2024	Systematic Review	Ann Rheum Dis	Efficacy/safety review informing 2023 EULAR psoriatic arthritis recommendations
31969328	2020	Guideline (EULAR)	Ann Rheum Dis	2019 update of EULAR RA management recommendations with synthetic/biologic DMARDs
37423647	2023	RCT	Ann Rheum Dis	NORD-STAR trial: certolizumab pegol vs abatacept, tocilizumab or active conventional therapy in early RA
33268527	2020	RCT	BMJ	Phase IV comparison of active conventional treatment vs three biologics in early RA
35296532	2022	Long-term follow-up (Phase 3 extension)	RMD Open	3-year safety/outcomes of CZP in non-radiographic axSpA (C-axSpAnd)
24919863	2014	Review	Drugs	Established EU/US indications for CZP: axSpA (AS and nr-axSpA) and psoriatic arthritis
34786446	2021	Case Report	JAAD Case Reports	Sole positive efficacy signal: CZP for leg ulcers due to rheumatoid vasculitis
31990069	2020	Case Report (adverse reaction)	J Clin Pharm Ther	Hypocomplementemic urticarial vasculitis induced during CZP treatment — contradicts vasculitis-indication hypothesis

Australia Market Information

Certolizumab pegol currently has no ARTG entries and is not marketed in Australia. All 10 predicted indications above would therefore require a new market-entry registration pathway rather than an indication-extension of an existing local product.

Safety Considerations

No TFDA/TGA Product Information data (key warnings, contraindications, or drug interactions) was returned for this drug in the Evidence Pack — this is logged as a Blocking data gap (DG001) that prevents formal S1 safety screening. Please refer to the TGA-approved Product Information (PI), once registration is pursued, for authoritative safety information.

In the interim, literature captured in this Evidence Pack surfaces class-level safety signals worth flagging for any repurposing decision:

Paradoxical vasculitis induction: multiple case reports describe certolizumab pegol causing leukocytoclastic vasculitis, hypocomplementemic urticarial vasculitis, medium-vessel vasculitis, and rapidly progressive glomerulonephritis (PMID 31990069, 28405087, 41158918, 32687015) — directly relevant to, and contradicting, the rheumatoid vasculitis prediction.
Infection risk: a comparative review of immune-modulatory drug SmPC data highlights serious infection as a recurring concern across this drug class (PMID 36418084).
Mechanistic contraindication signal: anti-TNF agents are known to increase risk of mycobacterial reactivation, which is directly counter-indicated in patients with IL-12/23 pathway defects (e.g. mendelian susceptibility to mycobacterial disease, rank 7) — this should be treated as a safety exclusion, not a treatment opportunity.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for inflammatory spondylopathy / vertebral disease only) — Research Question (polyarticular JIA, tenosynovitis) — Hold (rheumatoid vasculitis, mendelian susceptibility to mycobacterial disease, and all structural/congenital predictions)

Rationale:

Inflammatory spondylopathy and vertebral disease are backed by ≥2 completed Phase 3 RCTs plus systematic reviews (L1), and represent an established anti-TNF class indication simply awaiting Australian market registration — the clearest actionable opportunity in this pack.
Polyarticular JIA and tenosynovitis have plausible mechanisms but insufficient published evidence (single unpublished-result trial, or no trials at all) to move past a research question.
Rheumatoid vasculitis has a strong TxGNN score but is contradicted by the balance of safety literature, which shows the drug can induce rather than treat vasculitic disease; and mendelian susceptibility to mycobacterial disease represents a probable contraindication rather than an indication. The remaining structural/congenital predictions have zero supporting evidence and are best explained as knowledge-graph noise.

To proceed, the following is needed:

TGA-approved Product Information (PI) — warnings, contraindications, and drug interaction data (currently a Blocking data gap, DG001)
Detailed mechanism-of-action documentation from DrugBank (DG002)
Published results for the polyarticular JIA Phase 3 trial (NCT01550003) before advancing that indication
A formal causality review reconciling the vasculitis-induction case reports against the single positive case report before any further work on the rheumatoid vasculitis hypothesis
Confirmation that IL-12/23 pathway deficiency is listed as a contraindication/precaution in any future PI, given the mechanistic conflict identified above
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.